Author: Seyed Jafari, S. Morteza; Feldmeyer, Laurence; Bossart, Simon; Simon, Dagmar; Schlapbach, Christoph; Borradori, Luca
Title: Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid Cord-id: 1f4ijhco Document date: 2021_1_29
ID: 1f4ijhco
Snippet: Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.
Document: Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date